Xenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDA
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectivelyEnrollment in X-NOVA2 study in
Xenon Pharmaceuticals asked the FDA to approve a new seizure medicine. Watch to see if regulators think it works and is safe enough.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.